Tuesday, September 6, 2016

D-Day For KPTI Today

Karyopharm Therapeutics Inc. is slated to provide an overview of top-line results from its phase 2b study of oral Selinexor in multiple myeloma, dubbed STORM, today.

from RTT - Biotech http://ift.tt/2bPHGnb
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)